Make your money go further for just 25p per day


Animalcare: in the recovery room or more surgery needed?

24/09/2019 · Animalcare Group (ANCR) 

AIM Inheritance Tax UK

Small dog with Animalcare branding

This animal health business appeared to have a bright future when we covered it in an earlier research commentary. Unfortunately, the merger with an ambitious European animal healthcare business resulted in a host of problems and a material decline in the share price. With a new chief executive at the helm the future is thankfully looking brighter.

The sale of vaccines, medicines and medical devices for companion animals alone is a massive business, exceeding $8bn annually in 2018 with an additional $14bn in sales of vaccines and medicines for livestock. The sector is dominated by US listed Zoetis Inc, which was spun out of pharmaceutical giant Pfizer in 2012. Zoetis, which has a current market capitalisation of $60bn, has seen its share price rise threefold since its IPO and now trades at a heady…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Fundamental Asset Management
Buy any of our portfolios with our associates.


Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world


Become a Champion Investor for just £90 a year.


More on Animalcare Group

Coronavirus impact: 28 May - boohoo illustrates the perils of short selling

28/05/2020 · Company Insights

A properly constructed short attack should contain more damning evidence than the weak effort on boohoo,…

How can Hotel Chocolat keep defying challenges?

24/01/2020 · Company Insights

Strong results from the chocolate makers have justified a stretched valuation, but others haven’t been so…